News · eGov

A high-level panel at the 29th Bengaluru Tech Summit examined how artificial intelligence could accelerate drug discovery, diagnostics and personalised medicine while advancing India's AI sovereignty.
✦ AI SUMMARY 30-second read

- AI in drug discovery, diagnostics and personalised medicine was a central theme at the BTS 2026 session titled 'AI & Beyond: The Emerging India'.
- Panellists stressed that human expertise in validation, critical thinking and oversight must accompany AI-driven automation in scientific research.
- The discussion called on India to build indigenous AI capabilities covering data, computing infrastructure and tailored technological solutions.
Why it matters: India's biotechnology and pharmaceutical sectors could gain competitive global standing by linking research capabilities with homegrown AI infrastructure.

This summary was generated by AI. Editors may review and update it.
The 29th Bengaluru Tech Summit (BTS) 2026 hosted a panel discussion titled 'AI & Beyond: The Emerging India', bringing together senior figures from Karnataka's government, industry and the startup ecosystem to examine how artificial intelligence is reshaping scientific research and healthcare.

Among the participants were Priyank Kharge, Karnataka Minister for Home, Information Technology and Biotechnology and e-Governance; Kris Gopalakrishnan, Chairperson of the Vision Group on IT and Electronics, Government of Karnataka, and Co-Founder of Infosys; Dr Kiran Mazumdar-Shaw, Executive Chairperson of Biocon and Chairperson of the Vision Group on Biotechnology, Government of Karnataka; and Prashanth Prakash, Founding Partner at Accel India and Chairperson of the Vision Group on Startups. The session was moderated by Lingaraju Sawkar, President, Kyndryl APxJ.
The panellists assessed AI's potential to drive transformation across governance, healthcare, scientific research, agriculture, enterprise services and entrepreneurship, with drug discovery and biotechnology research emerging as a prominent area of focus.
What was discussed
AI's application in accelerating drug discovery was highlighted alongside improvements in diagnostics and the advancement of personalised medicine. The panel placed these opportunities within a broader conversation about developing healthcare solutions that are scalable, accessible and affordable.
For India's biotechnology and pharmaceutical ecosystem, the panellists pointed to the importance of connecting existing research capabilities with indigenous AI technologies and data infrastructure. Such integration, they suggested, could strengthen the country's capacity to develop and scale technology-led healthcare innovations.
The panel also underlined that AI-driven progress must be accompanied by human judgement. Validation, critical thinking, integration and oversight were identified as roles where human expertise remains essential, even as AI takes on a greater share of routine and analytical tasks.
AI sovereignty and indigenous innovation
A significant portion of the discussion centred on AI sovereignty — the need for India to exercise greater control over its data, computing infrastructure and technology development rather than depending on systems built elsewhere.
For biotechnology and pharmaceutical research specifically, access to appropriate data and computing capabilities was described as a foundation for building an indigenous innovation ecosystem. The panellists argued that India has the opportunity to develop AI solutions tailored to its own economic and societal needs while producing technologies of global relevance.
The panel also explored how AI could extend essential services to underserved communities, reinforcing the case for inclusive design in technology development.
What it means for India
The discussion at BTS 2026 reflected a growing consensus that AI's value in India extends well beyond productivity gains. Applied to biotechnology and pharmaceutical research, AI could support a more technology-driven model of scientific advancement — provided the country invests in the underlying infrastructure and expertise.
The emphasis on indigenous capabilities signals a policy direction in which India seeks to be a producer, not merely a consumer, of frontier AI technologies relevant to healthcare and life sciences.